n-(2,6-dimethylphenyl)-1-methyl-2-piperidinecarboxamidmonohydrochloride

n-(2,6-dimethylphenyl)-1-methyl-2-piperidinecarboxamidmonohydrochloride

mepivacaine hydrochloride

CAS: 1722-62-9

Molecular Formula: C15H22N2O.ClH

n-(2,6-dimethylphenyl)-1-methyl-2-piperidinecarboxamidmonohydrochloride - Names and Identifiers

Name	mepivacaine hydrochloride
Synonyms	Mepivacaine HCL Mepivacaine HCl USP carbocainehydrochloride mepivacaine hydrochloride dl-mepivacainehydrochloride Ropivacaine base Mepivacaine HCL Mepivacaine Hydrochloride (200 mg) 1-methyl-2',6'-pipecoloxylididehydrochloride 1-methyl-2',6'-pipecoloxylididehydrochloride 1-methyl-2',6'-pipecoloxylidine hydrochloride dl-1-methyl-2',6'-pipecoloxylididehydrochloride 6'-pipecoloxylidide,1-methyl-2monohydrochloride 2',6'-Pipecoloxylidide, 1-methyl-, monohydrochloride (6CI, 8CI) n-(2,6-dimethylphenyl)-1-methyl-2-piperidinecarboxamide hydrochloride n-(2,6-dimethylphenyl)-1-methyl-2-piperidinecarboxamidmonohydrochloride (1-methyl-dl-piperidine-2-carboxylicacid)-2,6-dimethylanilidehydrochloride 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-methyl-, monohydrochloride (9CI)
CAS	1722-62-9
EINECS	217-023-9
InChI	InChI=1/C15H22N2O.ClH/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3;/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18);1H

n-(2,6-dimethylphenyl)-1-methyl-2-piperidinecarboxamidmonohydrochloride - Physico-chemical Properties

Molecular Formula	C15H22N2O.ClH
Molar Mass	282.81
Melting Point	255-257°C (dec.)
Boling Point	383.1°C at 760 mmHg
Flash Point	185.5°C
Solubility	H2O: soluble20mg/mL, clear
Vapor Presure	4.52E-06mmHg at 25°C
Appearance	powder
Color	white to beige
Storage Condition	2-8°C
In vitro study	Mepivacaine hydrochloride binds to specific voltage-gated sodium ion channels in neuronal cell membranes, which inhibits both sodium influx and membrane depolarization. This leads to a blockage of nerve impulse initiation and conduction and results in a reversible loss of sensation. Compared to other local anesthetics, this agent has a more rapid onset and moderate duration of action. Mepivacaine hydrochloride has a reasonably rapid onset (more rapid than that of procaine) and medium duration of action (shorter than that of procaine). Mepivacaine hydrochloride displays a preferential use-dependent block of Na(v)1.8, S(-)-bupivacaine displays a preference for TTXs Na(+) channels.
In vivo study	Tests on horses have shown that mepivacaine has a greater spread between adjacent joint structures than postulated after latex injection based on previous dissections, in contrast to arthrographic studies. In patients undergoing knee arthroscopy, sonication reduced the minimum effective anesthetic volume (MEAV50) required for 1.5 mepivacaine blockade of the sciatic nerve by 37% compared to nerve stimulation. In canines and premolars, the use of lidocaine preparation 3% mepivacaine resulted in shorter intervals of anesthesia compared with epinephrine.

n-(2,6-dimethylphenyl)-1-methyl-2-piperidinecarboxamidmonohydrochloride - Risk and Safety

Hazard Symbols	Xn - Harmful
Risk Codes	22 - Harmful if swallowed
Safety Description	S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes.
UN IDs	UN 2811 6.1 / PGIII
RTECS	TK6475000
HS Code	29333990
Toxicity	LD50 in mice, rats (mg/kg): 280, 500 s.c. (Aberg)

n-(2,6-dimethylphenyl)-1-methyl-2-piperidinecarboxamidmonohydrochloride

View History

n-(2,6-dimethylphenyl)-1-methyl-2-piperidinecarboxamidmonohydrochloride

© 2015, 2023 ChemBK.com All Rights Reserved | Build: 20230617001